# Isabl **Source:** https://geo.sig.ai/brands/isabl **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** isabl.io **Last Updated:** 2026-04-14 ## Summary NYC YC W20 MSK Cancer Center spinout with FDA Breakthrough Device for whole-genome/transcriptome tumor profiling; $5M total (Two Sigma/NCI SBIR) competing with Foundation Medicine and Tempus AI for comprehensive genomic profiling in pediatric and rare cancers. ## Company Overview Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss. Isabl's whole-genome and transcriptome sequencing approach (WGS + WTS) generates more complete tumor genomic information than the targeted gene panel tests (which analyze 50-500 genes) that currently dominate clinical genomic oncology testing: WGS captures all 3 billion base pairs of the tumor genome (detecting structural variants, copy number alterations, mutational signatures, and tumor mutational burden) while WTS captures gene expression across all 20,000+ human genes (identifying fusion transcripts, expression-level changes in cancer driver pathways, and RNA-level splicing variants that DNA sequencing alone misses). The FDA Breakthrough Device Designation (granted for rare and pediatric cancers where comprehensive profiling is most needed) provides the regulatory framework for accelerated FDA review of the Isabl GxT platform as a companion diagnostic. The MSK Cancer Center incubation (one of the world's leading cancer research and treatment institutions) provides the clinical validation context that oncology diagnostic company formation requires. In 2025, Isabl competes in the cancer genomics diagnostics, comprehensive genomic profiling, and precision oncology market with Foundation Medicine (FDA-approved CGP tests, Roche subsidiary), Tempus AI (NASDAQ: TEM, AI-enabled precision medicine, $1.1B IPO 2024), and Guardant Health (NASDAQ: GH, liquid biopsy and CGP, $1.9B raised) for oncology tumor profiling and comprehensive genomic testing adoption. The NCI SBIR grant (competitive federal funding awarded to early-stage biomedical companies for high-priority cancer research) validates Isabl's scientific approach and provides non-dilutive capital for the pediatric oncology program development. Two Sigma Ventures' investment (quantitative finance and data science firm with deep computational biology conviction) reflects the machine learning integration in Isabl's genomic data analysis pipeline. The 2025 strategy focuses on clinical validation studies for the Isabl GxT in pediatric solid tumors, expanding the NCI partnership for rare cancer genomic profiling programs, and building the clinical laboratory infrastructure for CLIA-certified commercial testing. ## Frequently Asked Questions ### What is Isabl? Isabl is a biotechnology company founded in 2020 that offers comprehensive genomic testing for cancer patients. The company analyzes entire tumor genomes and transcriptomes to identify cancer-associated mutations for improved diagnosis and treatment. ### What products and services does Isabl offer? Isabl offers whole genome sequencing, transcriptome analysis, cancer genomic profiling, Isabl GxT testing, and pediatric cancer diagnostics. Their flagship Isabl GxT technology provides comprehensive tumor genome and transcriptome testing. ### Who can benefit from Isabl's services? Isabl's services are designed for cancer patients, with a particular focus on pediatric and rare solid cancers. Their genomic testing helps healthcare providers identify cancer-associated mutations for improved diagnosis and treatment decisions. ### When was Isabl founded? Isabl was officially founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015 to 2019. The company participated in Y Combinator's Winter 2020 batch. ### Where is Isabl located? Isabl is based in New York, NY. The company incubated at Memorial Sloan Kettering Cancer Center before its official founding. ### How much funding has Isabl raised? Isabl raised $3M in seed funding from investors including Two Sigma Ventures, Y Combinator, BoxOne Ventures, Bossa Invest, and Jude Gomilla. The company also secured a $2M SBIR grant from the National Cancer Institute (NCI) running from April 2023 to March 2025. ### What major achievements has Isabl earned? Isabl received FDA Breakthrough Device Designation for its Isabl GxT technology, a significant regulatory milestone. The company was also accepted into Y Combinator's Winter 2020 batch and secured substantial funding from top-tier investors and the National Cancer Institute. ### What makes Isabl's technology unique? Isabl's approach involves analyzing entire tumor genomes and transcriptomes rather than limited gene panels. Their FDA Breakthrough Device-designated Isabl GxT technology provides comprehensive genomic profiling to identify cancer-associated mutations for improved treatment decisions. ### How can I learn more about Isabl's services? Based on the provided information, Isabl is located in New York, NY and operates in the healthcare technology sector. Specific contact information is not included in the available details. ### What recent developments has Isabl announced? Isabl recently secured $3M in seed funding and a $2M NCI SBIR grant to advance Isabl GxT for pediatric and rare solid cancers through March 2025. The company also received FDA Breakthrough Device Designation for its Isabl GxT technology. ## Tags healthtech, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*